Zimbabwe is initiating a critical transition to safeguard its national HIV response, particularly the procurement and distribution of antiretroviral (ARV) drugs, as United States-funded health programmes are set to conclude this week. The National AIDS Council (NAC) has convened implementing partners to identify and absorb essential programmes into the national framework, prioritising interventions directly affecting patient access to treatment. This strategic move follows the US Embassy in Harare’s announcement last week that all funding for Zimbabwe’s health programmes would cease by month-end, after negotiations for a US$367 million five-year deal collapsed. The disagreement stemmed from Washington’s demand for access to biological samples for research and commercial purposes, coupled with its refusal to share potential benefits from future vaccines and treatments developed from them.
Key Players Involved
- National AIDS Council (NAC): Responsible for coordinating the transition and identifying critical HIV programmes for national absorption.
- United States Government: Withdrawing funding for Zimbabwe’s health programmes following collapsed negotiations.
- Zimbabwean Parliamentarians: Sensitised on the transition by NAC officials.
Event Timeline
- Last Week: US Embassy in Harare announces discontinuation of health funding.
- This Week (End of September 2026): US-funded health programmes in Zimbabwe officially wind down.
- Friday, September 25, 2026: NAC monitoring and evaluation director, Mr. Amon Mpofu, sensitised parliamentarians in Kadoma on the transition process.
